Malin shareholders in line for windfall after €119 million cash boost
Dublin-based biotech investment fund said €45 million of the proceeds from the sale will be used to repay a European Investment Bank loan, with the remaining cash to be returned to shareholders later this year
Malin, the Dublin-based biotech investment fund, said it will return capital to shareholders in the second half of this year following the sale of its stake in a drug company for up to €119 million.
Kymab, a Cambridge-based company developing treatments for the immune system, is being acquired by drug giant Sanofi in a deal worth up to $1.45 billion. Malin owns about 10 per cent of Kymab and will receive $112 million (€92 million)...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
Amryt seeks to have rare condition drug approved for payment
The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement
Icon to restore staff pay as business recovers from virus
Clinical trials firm reported 10.8% drop in revenues for the three months to the end of June
Comment: Cutting-edge pharma research can bring investment to Ireland
We have the potential to become Europe’s go-to destination for the development of advanced therapy medicinal products
Sandra Gannon: We must act now to stop medicines running out
The essential ingredients for common drugs are largely produced in the countries worst-hit by Covid-19. We could soon be facing shortages of antibiotics, paracetamol, statins and other medication
